Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity

Dual targeting of BCMA and B7-H3 with CAR T cells and BiPE synergistically enhances T cell activation, effector function, and cytotoxicity against MM. This combinatorial strategy has the potential to overcome resistance mechanisms and represents a promising therapeutic approach for improving outcomes in MM and other BCMA⁺/B7-H3⁺ malignancies.